ViiV Healthcare gains EU marketing approval for Triumeq PD

Global specialist HIV company ViiV Healthcare, which is majority owned by GSK (LSE: GSK) , has been granted marketing authorization by the European Medicines Agency (EMA) for Triumeq PD; a dispersible tablet of the fixed dose combination of abacavir, dolutegravir and lamivudine for children living with HIV-1 weighing 14kg to <25kg.

The authorization also includes the label extension of Triumeq tablet, lowering the minimum weight that a child with HIV-1 can be prescribed this medicine from 40kg to 25kg.

The EU approval comes nearly a year after the US Food and Drug Administration (FDA) approved the pediatric version of Triumeq in March 2022.